Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Digoxin | Research article

Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients

Authors: Daya Ram Parajuli, Sepehr Shakib, Joanne Eng-Frost, Ross A. McKinnon, Gillian E. Caughey, Dean Whitehead

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Background

Studies have demonstrated that heart failure (HF) patients who receive direct pharmacist input as part of multidisciplinary care have better clinical outcomes. This study evaluated/compared the difference in prescribing practices of guideline-directed medical therapy (GDMT) for chronic HF patients between two multidisciplinary clinics—with and without the direct involvement of a pharmacist.

Methods

A retrospective audit of chronic HF patients, presenting to two multidisciplinary outpatient clinics between March 2005 and January 2017, was performed; a Multidisciplinary Ambulatory Consulting Service (MACS) with an integrated pharmacist model of care and a General Cardiology Heart Failure Service (GCHFS) clinic, without the active involvement of a pharmacist.

Results

MACS clinic patients were significantly older (80 vs. 73 years, p < .001), more likely to be female (p < .001), and had significantly higher systolic (123 vs. 112 mmHg, p < .001) and diastolic (67 vs. 60 mmHg, p < .05) blood pressures compared to the GCHF clinic patients. Moreover, the MACS clinic patients showed more polypharmacy and higher prevalence of multiple comorbidities. Both clinics had similar prescribing rates of GDMT and achieved maximal tolerated doses of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HFrEF. However, HFpEF patients in the MACS clinic were significantly more likely to be prescribed ACEIs/ARBs (70.5% vs. 56.2%, p = 0.0314) than the GCHFS patients. Patients with both HFrEF and HFpEF (MACS clinic) were significantly less likely to be prescribed β-blockers and mineralocorticoid receptor antagonists. Use of digoxin in chronic atrial fibrillation (AF) in MACS clinic was significantly higher in HFrEF patients (82.5% vs. 58.5%, p = 0.004), but the number of people anticoagulated in presence of AF (27.1% vs. 48.0%, p = 0.002) and prescribed diuretics (84.0% vs. 94.5%, p = 0.022) were significantly lower in HFpEF patients attending the MACS clinic. Age, heart rate, systolic blood pressure (SBP), anemia, chronic renal failure, and other comorbidities were the main significant predictors of utilization of GDMT in a multivariate binary logistic regression.

Conclusions

Lower prescription rates of some medications in the pharmacist-involved multidisciplinary team were found. Careful consideration of demographic and clinical characteristics, contraindications for use of medications, polypharmacy, and underlying comorbidities is necessary to achieve best practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Al-Khazaali A, Arora R, Helu HK. Effective strategies in reducing rehospitalizations in patients with heart failure. Am J Ther. 2016;23(3):e799-804.PubMedCrossRef Al-Khazaali A, Arora R, Helu HK. Effective strategies in reducing rehospitalizations in patients with heart failure. Am J Ther. 2016;23(3):e799-804.PubMedCrossRef
2.
go back to reference Fry M, McLachlan S, Purdy S, Sanders T, Kadam UT, Chew-Graham CA. The implications of living with heart failure; the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Fam Pract. 2016;17(1):139.PubMedPubMedCentralCrossRef Fry M, McLachlan S, Purdy S, Sanders T, Kadam UT, Chew-Graham CA. The implications of living with heart failure; the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Fam Pract. 2016;17(1):139.PubMedPubMedCentralCrossRef
3.
go back to reference Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338–54.PubMedCrossRef Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338–54.PubMedCrossRef
4.
go back to reference Bergethon KE, Ju C, DeVore AD, Hardy NC, Fonarow GC, Yancy CW, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Trends in 30-day readmission rates for patients hospitalized with heart failure. Circ Heart Fail. 2016;9(6):e002594.PubMedCrossRef Bergethon KE, Ju C, DeVore AD, Hardy NC, Fonarow GC, Yancy CW, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Trends in 30-day readmission rates for patients hospitalized with heart failure. Circ Heart Fail. 2016;9(6):e002594.PubMedCrossRef
5.
go back to reference Chamberlain AM, St. Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, Finney Rutten LJ, Jiang R, Weston SA, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128(1):38–45.PubMedCrossRef Chamberlain AM, St. Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, Finney Rutten LJ, Jiang R, Weston SA, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128(1):38–45.PubMedCrossRef
6.
go back to reference Hopper I, Skiba M, Windebank E, Brack J, Tonkin A, Krum H. Polypharmacy in heart failure: Is reducing medication safe? Int J Cardiol. 2016;214:529–30.PubMedCrossRef Hopper I, Skiba M, Windebank E, Brack J, Tonkin A, Krum H. Polypharmacy in heart failure: Is reducing medication safe? Int J Cardiol. 2016;214:529–30.PubMedCrossRef
7.
go back to reference van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time: a systematic review. Eur J Heart Fail. 2016;18(3):242–52.PubMedCrossRef van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time: a systematic review. Eur J Heart Fail. 2016;18(3):242–52.PubMedCrossRef
8.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.PubMedCrossRef
9.
go back to reference Naing P, Forrester D, Kangaharan N, Muthumala A, Mon Myint S, Playford D. Heart failure with preserved ejection fraction. Aust J Gen Pract. 2019;48:465–71.PubMedCrossRef Naing P, Forrester D, Kangaharan N, Muthumala A, Mon Myint S, Playford D. Heart failure with preserved ejection fraction. Aust J Gen Pract. 2019;48:465–71.PubMedCrossRef
10.
go back to reference Özlek B, Özlek E, Kahraman S, Tekinalp M, Zencirkiran Agus H, Çelik O, Çil C, Doğan V, Başaran Ö, Kaya BC, et al. Gender disparities in heart failure with mid-range and preserved ejection fraction: results from APOLLON study. Anatol J Cardiol. 2019;21(5):242–52.PubMedPubMedCentral Özlek B, Özlek E, Kahraman S, Tekinalp M, Zencirkiran Agus H, Çelik O, Çil C, Doğan V, Başaran Ö, Kaya BC, et al. Gender disparities in heart failure with mid-range and preserved ejection fraction: results from APOLLON study. Anatol J Cardiol. 2019;21(5):242–52.PubMedPubMedCentral
11.
go back to reference Basaraba JE, Barry AR. Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacotherapy. 2015;35(4):351–60.PubMedCrossRef Basaraba JE, Barry AR. Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacotherapy. 2015;35(4):351–60.PubMedCrossRef
12.
go back to reference Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685–94.PubMedPubMedCentralCrossRef Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685–94.PubMedPubMedCentralCrossRef
13.
go back to reference Srivastava PK, Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range ejection fraction. Curr Heart Fail Rep. 2020;20:1230–9. Srivastava PK, Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range ejection fraction. Curr Heart Fail Rep. 2020;20:1230–9.
14.
go back to reference Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110(15):2180–3.PubMedCrossRef Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110(15):2180–3.PubMedCrossRef
15.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.PubMedCrossRef
16.
go back to reference Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52.PubMedPubMedCentralCrossRef Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52.PubMedPubMedCentralCrossRef
17.
go back to reference Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020;18(1):103.PubMedPubMedCentralCrossRef Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020;18(1):103.PubMedPubMedCentralCrossRef
18.
go back to reference Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6(2):166–73.PubMedPubMedCentralCrossRef Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6(2):166–73.PubMedPubMedCentralCrossRef
20.
go back to reference Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (borderline) ejection fraction. Clin Implic Future Directions. 2017;5(11):763–71. Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (borderline) ejection fraction. Clin Implic Future Directions. 2017;5(11):763–71.
21.
go back to reference Lakhani I, Leung KSK, Tse G, Lee APW. Novel mechanisms in heart failure with preserved, midrange, and reduced ejection fraction. Front Physiol. 2019;10:874–874.PubMedPubMedCentralCrossRef Lakhani I, Leung KSK, Tse G, Lee APW. Novel mechanisms in heart failure with preserved, midrange, and reduced ejection fraction. Front Physiol. 2019;10:874–874.PubMedPubMedCentralCrossRef
22.
go back to reference Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883–90.PubMedCrossRef Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883–90.PubMedCrossRef
23.
go back to reference Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26(24):2706–13.PubMedCrossRef Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26(24):2706–13.PubMedCrossRef
24.
go back to reference Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–84.PubMedCrossRef Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–84.PubMedCrossRef
25.
go back to reference Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev. 2015;12:Cd009889. Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev. 2015;12:Cd009889.
26.
go back to reference Shukkoor AA, George NE, Radhakrishnan S, Velusamy S, Kaliappan T, Gopalan R, Anandan P, Palanimuthu R, Balasubramanian VR. Impact of clinical audit on adherence to the guidelines directed medical therapy in patients admitted with heart failure. Curr Drug Saf. 2020;15(2):117–23.PubMedCrossRef Shukkoor AA, George NE, Radhakrishnan S, Velusamy S, Kaliappan T, Gopalan R, Anandan P, Palanimuthu R, Balasubramanian VR. Impact of clinical audit on adherence to the guidelines directed medical therapy in patients admitted with heart failure. Curr Drug Saf. 2020;15(2):117–23.PubMedCrossRef
27.
go back to reference Parajuli DR, Kourbelis C, Franzon J, Newman P, McKinnon RA, Shakib S, Whitehead D, Clark RA. Effectiveness of the pharmacist-involved multidisciplinary management of heart failure to improve hospitalizations and mortality rates in 4630 patients: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2019;25(9):744–56.PubMedCrossRef Parajuli DR, Kourbelis C, Franzon J, Newman P, McKinnon RA, Shakib S, Whitehead D, Clark RA. Effectiveness of the pharmacist-involved multidisciplinary management of heart failure to improve hospitalizations and mortality rates in 4630 patients: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2019;25(9):744–56.PubMedCrossRef
28.
go back to reference Al-Bawardy R, Cheng-Lai A, Prlesi L, Assafin M, Xu S, Chen K, Tandan S, Aneke CS, Murthy S, Piña IL. Heart failure postdischarge clinic: a pharmacist-led approach to reduce readmissions. Curr Probl Cardiol. 2019;44:100407.PubMedCrossRef Al-Bawardy R, Cheng-Lai A, Prlesi L, Assafin M, Xu S, Chen K, Tandan S, Aneke CS, Murthy S, Piña IL. Heart failure postdischarge clinic: a pharmacist-led approach to reduce readmissions. Curr Probl Cardiol. 2019;44:100407.PubMedCrossRef
29.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453–7.CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453–7.CrossRef
30.
go back to reference Shakib S, Dundon BK, Maddison J, Thomas J, Stanners M, Caughey GE, Clark RA. Effect of a multidisciplinary outpatient model of care on health outcomes in older patients with multimorbidity: a retrospective case control study. PLoS ONE. 2016;11(8):e0161382.PubMedPubMedCentralCrossRef Shakib S, Dundon BK, Maddison J, Thomas J, Stanners M, Caughey GE, Clark RA. Effect of a multidisciplinary outpatient model of care on health outcomes in older patients with multimorbidity: a retrospective case control study. PLoS ONE. 2016;11(8):e0161382.PubMedPubMedCentralCrossRef
31.
go back to reference Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67(6):698–704.PubMedCrossRef Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67(6):698–704.PubMedCrossRef
32.
go back to reference Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574–85.PubMedCrossRef Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574–85.PubMedCrossRef
33.
go back to reference Newton PJ, Davidson PM, Reid CM, Krum H, Hayward C, Sibbritt DW, Banks E, MacDonald PS. Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study. Med J Aust. 2016;204(3):113.e111-118.CrossRef Newton PJ, Davidson PM, Reid CM, Krum H, Hayward C, Sibbritt DW, Banks E, MacDonald PS. Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study. Med J Aust. 2016;204(3):113.e111-118.CrossRef
34.
go back to reference Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5(8):565–74.PubMedCrossRef Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5(8):565–74.PubMedCrossRef
35.
go back to reference Gomez-Otero I, Ferrero-Gregori A, Varela Roman A, Seijas Amigo J, Pascual-Figal DA, Delgado Jimenez J, Alvarez-Garcia J, Fernandez-Aviles F, Worner Diz F, Alonso-Pulpon L, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl ed). 2017;70(5):338–46.CrossRef Gomez-Otero I, Ferrero-Gregori A, Varela Roman A, Seijas Amigo J, Pascual-Figal DA, Delgado Jimenez J, Alvarez-Garcia J, Fernandez-Aviles F, Worner Diz F, Alonso-Pulpon L, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl ed). 2017;70(5):338–46.CrossRef
36.
go back to reference Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10(6):100407.CrossRef Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10(6):100407.CrossRef
37.
go back to reference Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012.PubMedPubMedCentralCrossRef Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012.PubMedPubMedCentralCrossRef
38.
go back to reference Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178–86.PubMedCrossRef Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178–86.PubMedCrossRef
39.
go back to reference Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, McGwin G, Cutter GR, Allman RM, Prabhu SD, et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014;127(2):132–9.PubMedCrossRef Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, McGwin G, Cutter GR, Allman RM, Prabhu SD, et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014;127(2):132–9.PubMedCrossRef
40.
go back to reference Khalil V, Danninger M, Wang W, Khalil H. An audit of adherence to heart failure guidelines in an Australian hospital: a pharmacist perspective. J Eval Clin Pract. 2017;23(6):1195–202.PubMedCrossRef Khalil V, Danninger M, Wang W, Khalil H. An audit of adherence to heart failure guidelines in an Australian hospital: a pharmacist perspective. J Eval Clin Pract. 2017;23(6):1195–202.PubMedCrossRef
41.
go back to reference Suzuki M, Matsue Y, Izumi S, Kimura A, Hashimoto T, Otomo K, Saito H, Suzuki M, Kato Y, Funakoshi R. Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication. Heart Vessels. 2018;33(6):615–22.PubMedCrossRef Suzuki M, Matsue Y, Izumi S, Kimura A, Hashimoto T, Otomo K, Saito H, Suzuki M, Kato Y, Funakoshi R. Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication. Heart Vessels. 2018;33(6):615–22.PubMedCrossRef
42.
go back to reference Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110(6):724–31.PubMedCrossRef Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110(6):724–31.PubMedCrossRef
43.
go back to reference Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM Int J Med. 2015;108(11):879–84.CrossRef Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM Int J Med. 2015;108(11):879–84.CrossRef
44.
go back to reference Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525–35.CrossRef Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525–35.CrossRef
45.
go back to reference Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLoS ONE. 2019;14(2):e0212907–e0212907.PubMedPubMedCentralCrossRef Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLoS ONE. 2019;14(2):e0212907–e0212907.PubMedPubMedCentralCrossRef
46.
go back to reference Kim J-Y, Kim H-J, Jung S-Y, Kim K-I, Song HJ, Lee J-Y, Seong J-M, Park B-J. Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord. 2012;12(1):60.PubMedPubMedCentralCrossRef Kim J-Y, Kim H-J, Jung S-Y, Kim K-I, Song HJ, Lee J-Y, Seong J-M, Park B-J. Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord. 2012;12(1):60.PubMedPubMedCentralCrossRef
47.
go back to reference Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464–74.PubMedCrossRef Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464–74.PubMedCrossRef
48.
go back to reference Levitan EB, Van Dyke MK, Loop MS, O’Beirne R, Safford MM. Barriers to beta-blocker use and up-titration among patients with heart failure with reduced ejection fraction. Cardiovasc Drugs Ther. 2017;31(5):559–64.PubMedCrossRef Levitan EB, Van Dyke MK, Loop MS, O’Beirne R, Safford MM. Barriers to beta-blocker use and up-titration among patients with heart failure with reduced ejection fraction. Cardiovasc Drugs Ther. 2017;31(5):559–64.PubMedCrossRef
49.
go back to reference Phillips SM, Tofler GH, Marton RL. Barriers to diagnosing and managing heart failure in primary care. Med J Aust. 2004;181(2):78–81.PubMedCrossRef Phillips SM, Tofler GH, Marton RL. Barriers to diagnosing and managing heart failure in primary care. Med J Aust. 2004;181(2):78–81.PubMedCrossRef
50.
go back to reference Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167(6):2695–9.PubMedCrossRef Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167(6):2695–9.PubMedCrossRef
51.
go back to reference Chen XJ, Barywani SB, Hansson PO, Östgärd Thunström E, Rosengren A, Ergatoudes C, Mandalenakis Z, Caidahl K, Fu ML. Impact of changes in heart rate with age on all-cause death and cardiovascular events in 50-year-old men from the general population. Open Heart. 2019;6(1):e000856.PubMedPubMedCentralCrossRef Chen XJ, Barywani SB, Hansson PO, Östgärd Thunström E, Rosengren A, Ergatoudes C, Mandalenakis Z, Caidahl K, Fu ML. Impact of changes in heart rate with age on all-cause death and cardiovascular events in 50-year-old men from the general population. Open Heart. 2019;6(1):e000856.PubMedPubMedCentralCrossRef
52.
go back to reference Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc. 2017;6(12):e006540.PubMedPubMedCentralCrossRef Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc. 2017;6(12):e006540.PubMedPubMedCentralCrossRef
53.
go back to reference Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or digoxin for atrial fibrillation and heart failure? Cardiac Fail Rev. 2016;2(1):35–9.CrossRef Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or digoxin for atrial fibrillation and heart failure? Cardiac Fail Rev. 2016;2(1):35–9.CrossRef
54.
go back to reference Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6(9):e1008–18.PubMedCrossRef Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6(9):e1008–18.PubMedCrossRef
55.
go back to reference Mehta PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM Int J Med. 2004;97(3):133–9.CrossRef Mehta PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM Int J Med. 2004;97(3):133–9.CrossRef
56.
go back to reference Follath F. Challenging the dogma of high target doses in the treatment of heart failure: Is more always better? Arch Cardiovasc Dis. 2009;102(11):785–9.PubMedCrossRef Follath F. Challenging the dogma of high target doses in the treatment of heart failure: Is more always better? Arch Cardiovasc Dis. 2009;102(11):785–9.PubMedCrossRef
58.
go back to reference Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, Peterson ED. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750-755.e751.PubMedCrossRef Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, Peterson ED. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750-755.e751.PubMedCrossRef
59.
go back to reference Polsinelli VB, Shah SJ. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother. 2017;18(4):399–409.PubMedPubMedCentralCrossRef Polsinelli VB, Shah SJ. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother. 2017;18(4):399–409.PubMedPubMedCentralCrossRef
60.
go back to reference Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–92.PubMedCrossRef Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–92.PubMedCrossRef
61.
go back to reference Wong DT, Clark RA, Dundon BK, Philpott A, Molaee P, Shakib S. Caveat anicula! Beware of quiet little old ladies: demographic features, pharmacotherapy, readmissions and survival in a 10-year cohort of patients with heart failure and preserved systolic function. Med J Aust. 2010;192(1):9–13.PubMedCrossRef Wong DT, Clark RA, Dundon BK, Philpott A, Molaee P, Shakib S. Caveat anicula! Beware of quiet little old ladies: demographic features, pharmacotherapy, readmissions and survival in a 10-year cohort of patients with heart failure and preserved systolic function. Med J Aust. 2010;192(1):9–13.PubMedCrossRef
62.
go back to reference Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail. 2004;6(5):663–8.PubMedCrossRef Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail. 2004;6(5):663–8.PubMedCrossRef
63.
go back to reference Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.PubMedPubMedCentralCrossRef Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.PubMedPubMedCentralCrossRef
64.
go back to reference Vizzardi E, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, Trichaki E, Raddino R, Metra M. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. IJC Heart & Vessels. 2014;3:6–14.CrossRef Vizzardi E, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, Trichaki E, Raddino R, Metra M. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. IJC Heart & Vessels. 2014;3:6–14.CrossRef
65.
go back to reference Ho TH, Caughey GE, Shakib S. Guideline Compliance in chronic heart failure patients with multiple comorbid diseases: evaluation of an individualised multidisciplinary model of care. PLoS ONE. 2014;9(4):e93129.PubMedPubMedCentralCrossRef Ho TH, Caughey GE, Shakib S. Guideline Compliance in chronic heart failure patients with multiple comorbid diseases: evaluation of an individualised multidisciplinary model of care. PLoS ONE. 2014;9(4):e93129.PubMedPubMedCentralCrossRef
Metadata
Title
Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients
Authors
Daya Ram Parajuli
Sepehr Shakib
Joanne Eng-Frost
Ross A. McKinnon
Gillian E. Caughey
Dean Whitehead
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-01868-z

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue